Effect of recombinant human erythropoietin on insulin resistance in hemodialysis patients

Hemodialysis International

Volumn 13, Issue 3, 2009, Pages 340-346

  Khedr, Essam ^a   El Sharkawy, Magdy ^a   Abdulwahab, Saed ^a   Eldin, Essam Nor ^a   Ali, Medhat ^a   Youssif, Abla ^a   Ahmed, Bassam ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Hemodialysis; HOMA IR; Insulin resistance; rHuEPO

Indexed keywords

ALBUMIN; CALCIUM; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; IRON; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PARATHYROID HORMONE; PHOSPHATE; RECOMBINANT ERYTHROPOIETIN; TRIACYLGLYCEROL;

ADULT; ALBUMIN BLOOD LEVEL; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; FEMALE; GLUCOSE BLOOD LEVEL; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; IRON DEFICIENCY; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

BLOOD GLUCOSE; CASE-CONTROL STUDIES; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HUMANS; INSULIN; INSULIN RESISTANCE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 69249171375     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2009.00367.x     Document Type: Article

References (15)

1. Stolar MW. Insulin resistance, diabetes and the adipocyte. Am J Health System Pharma I. 2002; 59(Suppl): S3-S8.
2. Stefanović V, Nesić V, Stojimirović B. Treatment of insulin resistance in uremia. Int J Artif Organs. 2003; 26:100-104.
3. Kobayashi S, Maejima S, Ikeda T, Nagase M. Impact of dialysis therapy on insulin resistance in ESRD: Comparison of hemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant. 2000; 15:65-70.
4. Spaia S, Pangalos M, Askepidis N, et al. Effect of short-term rHuEPO treatment on insulin resistance in hemodialysis patients. Nephron. 2000; 84:320-325.
5. Rasic-Milutinovic Z, Perunicic-Pekovic G, Pljesa S. Clinical significance and pathogenic mechanisms of insulin resistance in chronic renal insufficiency (part II): Pathogenic factors of insulin resistance in chronic renal insufficiency. Med Pregl. 2000; 53:159-163.
6. Matthews OR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28:412-419.
7. The National Kidney Foundation NKF K/DOQI Clinical practice guidelines 2000. Available from: http://www.kidney.org/professionals/doqi/guidelines
8. Herman MP, Levy JC, Matthews DR. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care. 1998; 21:2191-2192.
9. Flakoll DJ, Jensen MD, Cherrington AD., In: Le Roith D, Taylor SL, eds. Phsiologic Action of Insulin in DM. A Fundamental and Clinical Text. 3rd ed. Philadelphia, Lippincott Williams and Wilkins. 2004; 165-181.
10. Chagnac A, Korzets A, Zevin D, et al. Effect of erythropoietin on glucose tolerance in hemodialysis patients. Clin Nephrol. 1994; 42:398-400.
11. Tuzcu A, Bahceci M, Yilmaz E, Bahceci S, Tuzcu S. The comparison of insulin sensitivity in non-diabetic hemodialysis patients treated with and without recombinant human erythropoietin. Horm Metab Res. 2004; 36:716-20.
12. Stefanović V, Djardjevic V, Mitic M. Lymphocyte cell membrane glycoprotein 1 (PC-1) in patients on maintenance hemodialysis treated with human erythropoietin. Ann Clin Biochem. 2005; 42:55-60.
13. Mak RH. Metabolic effects of erythropoietin in patients on peritoneal dialysis. Pediatr Nephrol. 1998; 12:550-665.
14. Wu Z, Bao X. Effects of benazepril on insulin resistance and glucose tolerance in uremia. Glin Nephrol. 1998; 50:108-112.
15. Mak RH. 1,25 dihydroxycholecalciferol corrects glucose intolerance in hemodialysis patients. Kidney Int. 1992; 41:1048-1054.